Illumina, Inc. $ILMN Shares Acquired by California Public Employees Retirement System

California Public Employees Retirement System raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 1.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 334,139 shares of the life sciences company’s stock after purchasing an additional 3,477 shares during the quarter. California Public Employees Retirement System owned 0.22% of Illumina worth $41,186,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Elyxium Wealth LLC acquired a new position in Illumina during the fourth quarter worth about $25,000. Creative Capital Management Investments LLC lifted its position in shares of Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares during the period. TD Waterhouse Canada Inc. acquired a new stake in shares of Illumina during the 4th quarter valued at approximately $26,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina during the 4th quarter worth approximately $26,000. Finally, Activest Wealth Management boosted its stake in shares of Illumina by 671.9% during the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 215 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ILMN. TD Cowen restated a “hold” rating on shares of Illumina in a research report on Wednesday, July 15th. Citigroup boosted their price objective on shares of Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Sanford C. Bernstein initiated coverage on shares of Illumina in a research note on Friday, June 26th. They issued a “market perform” rating and a $185.00 price objective on the stock. Piper Sandler increased their price objective on shares of Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 1st. Finally, Royal Bank Of Canada initiated coverage on shares of Illumina in a report on Thursday, May 14th. They set an “outperform” rating and a $170.00 target price for the company. Nine research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $156.88.

Illumina Stock Performance

Illumina stock opened at $184.68 on Tuesday. The stock has a fifty day moving average price of $167.28 and a 200 day moving average price of $143.77. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $196.66. The firm has a market capitalization of $27.94 billion, a P/E ratio of 33.58, a PEG ratio of 3.49 and a beta of 1.47. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.56.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same period last year, the company earned $0.97 EPS. The firm’s quarterly revenue was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts anticipate that Illumina, Inc. will post 5.22 earnings per share for the current year.

Insider Activity at Illumina

In related news, insider Scott M. Davies sold 615 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $180.00, for a total transaction of $110,700.00. Following the completion of the transaction, the insider owned 20,953 shares of the company’s stock, valued at approximately $3,771,540. This represents a 2.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the transaction, the director directly owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This represents a 7.67% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 1,003,769 shares of company stock valued at $155,710,908 in the last ninety days. 2.90% of the stock is owned by company insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.